



## *World Journal of Pharmaceutical Science & Technology*

Journal homepage: [www.wjpst.com](http://www.wjpst.com)

### Original Research Article

## DESIGN AND DEVELOPMENT OF FAST DISSOLVING FILM OF PIOGLITAZONE HYDROCHLORIDE

**Hapse Sandip A.<sup>1</sup>, Raut Rohit .B<sup>2</sup>, Shinde Ranjit.L<sup>3</sup>, Phalke Snehal .B<sup>4</sup>**

1. DR.V.VP.F'S College of Pharmacy, Vilad Ghat, Ahmednagar
2. DR.V.VP.F'S College of Pharmacy, Vilad Ghat, Ahmednagar
3. DR.V.VP.F'S College of Pharmacy, Vilad Ghat, Ahmednagar
4. DR.V.VP.F'S College of Pharmacy, Vilad Ghat, Ahmednagar

#### Address for correspondence:

**Hapse Sandip Appasaheb**, DR.V.VP.F'S College of Pharmacy, Vilad Ghat, Ahmednagar

E-mail- sandiphapse@gmail.com

Received: 15-4-2022, Revised: 29-4-2022, Accepted: 30-4-2022

### ABSTRACT

Pioglitazone is a antidiabetic drug, which undergoes hepatic degradation and have poor bioavailability (40%). For overcoming this problem Fast dissolving film of Pioglitazone Hydrochloride is formulated by employing Solvent casting technique with suitable film forming agent; HPMC and Sodium Starch glycolate in a different proportion. The prepared film avoids extensive first pass metabolism and improvement in dissolution efficacy, disintegration time which results in improvement in bioavailability. The advantage of this formulation is such that in case of shoot of blood glucose level in patient can take the drug without the usage of water. Therefore the main objective of the present work is to develop Fast dissolving films for Pioglitazone Hydrochloride to improve bioavailability, disintegration time, dissolution efficacy and patient compliance.

**KEYWORDS:** Solvent Casting Technique, Film forming agent, Sodium Starch Glycolate, Betacyclodextrine

### INTRODUCTION


Antidiabetic drugs, which undergoes hepatic degradation, which have poor bioavailability for overcoming this problem fast disintegrating film (FDF) of antidiabetic drugs can be formulated which avoids first pass metabolism and improvement in dissolution efficacy, disintegration time which results in

improvement in bioavailability. The advantage of this formulation is such that in case of shoot blood glucose level in patient can take the drug without the usage of water. Therefore the main objective of the present work is to develop fast disintegrating films (FDF) for antidiabetic drug to improve bioavailability, disintegration time, dissolution efficacy and increase patient compliance.

Despite of tremendous advancements in drug delivery, Oral routes of drug administration have wide acceptance up to 50-60% of total dosage forms due to ease of ingestion, pain avoidance, versatility (to accommodate various types of drug candidates), and, most importantly, patient compliance. Also, solid oral delivery systems do not require sterile conditions and are, therefore, less expensive to manufacture. The aforementioned advantages of drug administration via the oral cavity offer new possibilities in the administration of drugs to “problematical” subpopulations like children and the elderly. These patients have special drug administration requirements as they are often unable to swallow solid dosage forms (e.g. tablets, capsules). Poor taste can also lead to medication being refused or spat out. Furthermore, the pediatric subpopulation is a very heterogeneous group. Fast-dissolving solid drug dosage forms for application onto the oral cavity for the Pediatric population seem to be very appropriate, especially in preterm and term newborn infants.

Fast-dissolving oral delivery systems are solid dosage forms, which disintegrate or dissolve within 1 min when placed in the mouth without drinking of water or chewing. More recently, fast-dissolving films which dissolve/disintegrate in the mouth within a few seconds without additional water and the need to swallow are gaining interest as an alternative to fast-dissolving tablets to definitely eliminate patients’ fear of choking and overcome patient impediments.

Pioglitazone Hydrochloride is rapidly and completely absorbed from the gastrointestinal tract but is subject to saturable first pass hepatic metabolism. Bioavailability of about 40% has been reported after a 15mg dose at steady state. The pharmacokinetics of Pioglitazone Hydrochloride is non-linear due to the saturable first-pass hepatic metabolism and an increase in dose may produce a disproportionate increase in plasma concentration. There is also considerable inter individual variation in plasma drug concentrations. Pioglitazone Hydrochloride is more than 95% bound to plasma proteins and extensively metabolized in the liver and is excreted in the urine and faeces, mainly as inactive metabolites. The terminal plasma half-life is about 9 hrs, thus steady-state plasma concentrations are achieved after 7 days of dosing twice times daily.



**Fig. 1 Structure of Pioglitazone Hydrochloride**

## METHOD

### Pre-formulation studies<sup>2,3</sup>

It is one of the important prerequisites in development of any drug delivery system. Preformulation studies of the drug were performed, which included melting point determination, solubility and compatibility studies.

### Identification of Pioglitazone Hydrochloride

Identification of Pioglitazone Hydrochloride was carried out by the following techniques:

- a. UV spectroscopy
- b. IR spectroscopy

#### a. UV spectroscopy: Determination of $\lambda_{\max}$ of Pioglitazone Hydrochloride in methanol:

Standard stock solution of Pioglitazone Hydrochloride was prepared by dissolving accurately weighed 10 mg of Pioglitazone Hydrochloride in the little quantity of methanol in 100 ml volumetric flask. The volume was then made-up mark by using methanol, so as to get the solution of 100  $\mu\text{g/ml}$ .

From the standard stock solution, 1 ml was diluted to 10 ml with modified phosphate buffer solution (pH 7.4). The resulting solution containing 10  $\mu\text{g/ml}$  was scanned between 200 to 270 nm and  $\lambda_{\max}$  Pioglitazone Hydrochloride in methanol were observed.

#### b. Drug polymer interaction (FTIR) study

FTIR spectroscopy was performed on Fourier transformed infrared spectrophotometer (IR-Affinity-1, Shimadzu, Japan). The pellets of drug and potassium bromide were prepared by compressing the powders at 20 psi for 10 min on KBr press and the spectra were scanned in the wave number range of 4000- 600  $\text{cm}^{-1}$ . FTIR study was carried on Pioglitazone Hydrochloride physical mixture and super disintegrants.

#### c. Determination of solubility<sup>3,4</sup>

The solubility of Pioglitazone Hydrochloride was determined according to the method adopted by krishniah. An excess amount of drug was taken and dissolved in a measured volume of distilled water in a glass vial to get a saturated solution. The solution was sonicated and kept at room temperature for the attainment of equilibrium. The concentration of Pioglitazone Hydrochloride in the filtrate were determined spectrophotometrically by measuring at 353 nm after 24 h.

The solubility of Pioglitazone Hydrochloride in chloroform, methanol, ethanol, n-butanol, distilled water and acetone were also performed.

#### e. Determination of melting point<sup>5</sup>

Melting point of the drug was determined by taking small amount of drug in a capillary tube closed at one end. The capillary tube was placed in a melting point apparatus and the temperature at which drug melts was recorded. This was performed thrice and average value was noted.

#### f. Determination of partition coefficient<sup>4</sup>

The known quantity of drugs was added into 5 ml of 1-octanol separately and it was mixed with 5 ml of water in a separating funnel. Then two phases were allowed to equilibrate at 37°C for 24 h with intermittent shaking.

The concentration of the drug in the aqueous phase and organic phase was determined by UV spectroscopic method after necessary dilution. The apparent partition coefficient ( $K_p$ ) was calculated as the ratio of drug concentration in each phase by the following formula;

$$K_p = \frac{C_{org}}{C_{aq}}$$

Where,  $C_{org}$  is concentration of drug in organic phase and  $C_{aq}$  is the concentration of drug in aqueous phase.

#### g. Drug polymer compatibility

Pure drug and polymers were subjected to FTIR studies alone and in combinations. 3 mg of pure drug / combination of drug - polymer were triturated with 97 mg of potassium bromide in a smooth mortar. The mixtures were placed in the sample holder and were analyzed by FTIR to study the interference of polymers with the drug.

#### Preparation of Fast dispersible films of Pioglitazone Hydrochloride

Fast dissolving films of Pioglitazone Hydrochloride was prepared by solvent casting technique for the formulations shown

**Table No.1:** Composition of different formulations containing NC-HCL

Compositions	F-1	F-2	F-3	F-4	F-5	F-6	F-7	F-8	F-9
<b>Pioglitazone Hydrochloride (mg)</b>	15	15	15	15	15	15	15	15	15
<b>HPMC</b>	1	3	5	7	9	11	13	15	17
<b>PEG</b>	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
<b>Mannitol</b>	10	10	10	10	10	10	10	10	10
<b>Tween-80</b>	2	2	2	2	2	2	2	2	2
<b>Citric acid</b>	15	15	15	15	15	15	15	15	15
<b>SSG</b>	19	18	16	14	12	11	10	9	8
<b>Betacyclodextrine</b>	1	2	4	6	8	9	10	11	12
<b>Water</b>	Q.s	Q.s	Q.s	Qs	Q.s	Qs	Q.s	Qs	Q.s

## Evaluation of films of Pioglitazone Hydrochloride

**a. Identification**<sup>6</sup>-The films containing Pioglitazone HCl subjected to InfraRed studies for identification and to study drug polymer compatibility. (IR 8400S, Shimadzu, Japan). The KBr disk method was used for preparation of samples and the spectra were recorded over the wave number 4000 to 400  $\text{cm}^{-1}$ .

**b. Morphological properties**<sup>7</sup>-Properties such as homogeneity, color, transparency and surface of the oral films were evaluated by visually inspection.

**c. Uniformity of dosage units of the oral strips**<sup>8</sup>-The content uniformity of dosage units of the oral film preparation was tested using UV spectroscopy. According to the USP standards, the contents of preparations should lie between the limits 98 to 101%. The results were expressed as mean of six determinations of each formulation and mean  $\pm$  S.D calculated. The drug content was determined by using a standard calibration curve.

Preparation of standard calibration curve of Pioglitazone Hydrochloride in phosphate buffer solution (6.8 pH): 100 mg of Pioglitazone Hydrochloride was accurately weighed and dissolved in phosphate buffer 6.8 pH into a volumetric flask and the volume made upto 100ml with the same. 10 ml of this stock solution was taken and made up to 100 ml with phosphate buffer solution, which gives 100 mcg/ml concentrations (working standard). From this working standard, aliquots of 1.0, 3.0, 5.0, 7.0, 9.0 and 11.0 ml was pipetted into 50ml volumetric flask and the volume was made upto 50 ml with phosphate buffer 6.8 pH. The absorbance of the diluted solution was measured at 274nm against reagent blank (phosphate buffer 6.8 pH) in triplicate and a standard plot was drawn using the mean data obtained. The correlation coefficient was calculated by linear regression analysis.

**d. Film mass**-The mass of films was determined by an analytical balance. This test was performed on six films of each formulation and mean  $\pm$  S.D calculated.

**e. Film thickness**-Film thicknesses were determined using the Digimatic & Vernier Caliper. Each wafer was measured at five positions (central and the four corners) and the mean thickness was calculated. This test was performed on six films of each formulation and mean  $\pm$  S.D calculated.

**f. Folding endurance study**<sup>9</sup>-It was measured manually for the prepared fast dissolving film (3 X 2 cm). A strip was repeatedly folded at the same place till it broke. The number of times the film could be folded at the same place without breaking gave the value of folding endurance. This test was performed on six films of each formulation and mean  $\pm$  S.D calculated.

**g. Surface pH study**<sup>10</sup>-The surface pH of fast dissolving strip was determined in order to investigate the possibility of any side effects in vivo. As an acidic or alkaline pH may cause irritation to the oral mucosa, it was determined to keep the surface pH as close to neutral as possible. A combined pH electrode was used for

this purpose. Oral strip was slightly wet with the help of water. The pH was measured by bringing the electrode in contact with the surface of the oral film. This study was performed on six films of each formulation and mean  $\pm$  S.D calculated.

**h. In vitro disintegration studies**<sup>11</sup>-Disintegration time gives an indication about the disintegration characteristics and dissolution characteristics of the film. The film as per the dimensions (2x2 cm) required for dose delivery was placed on a stainless steel wire mesh placed in a petridish containing 10 ml phosphate buffer pH 6.8. Time required for the film to break was noted as in vitro disintegration time. This test was performed on six films of each formulation and mean  $\pm$  S.D calculated.

**i. Dissolution and drug release**<sup>12-16</sup>-Dissolution test of Pioglitazone HCl films was performed using (900 ml; phosphate buffer pH 6.8 with USP dissolution apparatus II (Labindia, Mumbai, India) at 50 rpm and  $37\pm 0.5^\circ\text{C}$  temperature. The drug release was analyzed spectrophotometrically at  $\lambda_{\text{max}}$  274nm using ultraviolet (UV) spectrophotometer (Shimadzu model) by using a calibration. One film was placed into each vessel and Test sample (5 mL) was withdrawn at particular time interval (10, 20, 30 and 40 Sec) and replaced with fresh dissolution media maintained at  $37\pm 0.5^\circ\text{C}$ ). This test was performed on six films of each formulation and mean  $\pm$  S.D calculated.

## RESULT AND DISCUSSION

### PREFORMULATION STUDIES

❖ **The following preformulation studies were performed for Pioglitazone Hydrochloride.**

**Table No. 2** Preformulation data of Pioglitazone Hydrochloride

	<b>Pioglitazone Hydrochloride</b>
<b><math>\lambda_{\text{max}}</math> in 0.1N CL</b>	274 nm
<b>Melting Point</b>	183- 184 $^\circ\text{C}$
<b>Partition coefficient</b>	2.72-3.73


### ➤ **Solubility of Pioglitazone Hydrochloride in other solvents**

Pioglitazone Hydrochloride is highly soluble in 0.1 N HCl. Practically insoluble in water, but freely soluble in DMSO.

### **Calibration curve**


**Table 3** Absorbance data for the calibration curve of Pioglitazone Hydrochloride in pH 6.8 buffer

Pioglitazone		
Sr. No.	Concentration (µg/ml)	Absorbance
1	10	0.24
2	20	0.47
3	30	0.74
4	40	1.01
5	50	1.30




**Fig 3** Standard calibration curve of Pioglitazone Hydrochloride in pH 6.8 buffer.


➤ **Drug – Excipients compatibility studies**



**Fig 6.** IR spectrum of Pioglitazone Hydrochloride



**Fig 7** IR spectrum of HPMC



**Fig 8** IR spectrum of physical mixture of Pioglitazone Hydrochloride and HPMC

## FORMULATION STUDY

### a. Physical characteristics

Characteristics such as homogeneity, color, transparency and surface of the oral films were evaluated by visual inspection. All films were totally homogenous, absolutely transparent, colorless, both sides smooth.

### Table No. 4 Evaluation of the Pioglitazone Hydrochloride Fast Dissolving Film



Formulation code	Uniformity of Dosage	Film Mass mg	Film Thickness mm	Surface pH	Folding Endurance
F-1	99.92±0.44	56.30±1.00	0.204±0.002	6.77±0.06	90.33±1.15
F-2	99.72±1.87	57.21±1.85	0.2±0.008	6.85±0.06	96.33±1.15
F-3	98.32±0.34	56.45±1.91	0.204±0.001	6.80±0.07	98.33±0.57
F-4	99.53±1.15	58.39±1.27	0.204±0.001	6.85±0.06	94.66±1.52
F-5	98.81±0.55	56.06±1.84	0.206±0.001	6.82±0.11	98.00±1.0
F-6	100.22±0.50	59.03±1.55	0.205±0.001	6.86±0.07	95.33±1.15
F-7	100.70±0.89	57.87±1.27	0.206±0.004	6.83±0.12	98.33±0.57
F-8	98.17±0.57	58.08±1.29	0.203±0.002	6.86±0.05	96.66±1.52
F-9	99.48±0.78	58.54±1.56	0.199±0.005	6.82±0.09	97.33±0.57

S.D\*: Standard deviation of three determinations

#### g. In vitro disintegration studies

All the fast dissolving films of each formulation were found disintegrate in less than 30 sec. F7 formulation found to gave minimum disintegration time (20.23±0.75) as compared F1 formulation (22.41±0.57).


#### h. In vitro Dissolution and release

*In vitro* dissolution and release studies of various formulations were performed using pH 6.8 phosphate buffer as dissolution medium and measuring drug concentration spectrophotometrically at 274 nm by using a calibration. The *in vitro* drug release profile from the films of formulae F1 and F2 in phosphate buffer pH 6.8. After 20 seconds time interval more than 75% drug was released from films. Drug release rate was very good with films containing HPMC E6 as a polymer.

#### Table 5 In-vitro drug release data of fast dissolving films of Pioglitazone Hydrochloride

Sr. No.	Time (min.)	% Cumulative drug release								
		F1	F2	F3	F4	F5	F6	F7	F8	F9
1	0	0	0	0	0	0	0	0	0	0
2	2	29.11	31.45	32.15	34.17	39.55	43.02	30.22	35.21	32.64
3	4	34.61	38.65	39.19	45.23	48.83	48.12	49.14	46.34	49.26
4	6	53.54	59.31	59.56	61.25	64.99	69.24	65.11	60.17	67.44
5	8	71.32	74.65	74.98	75.03	79.23	76.47	72.56	68.34	75.65
6	12	86.67	88.51	88.89	87.37	90.20	87.32	83.34	81.12	87.13
7	14	94.82	92.72	93.83	91.49	95.73	93.61	96.78	91.56	94.76

**Fig 8** *In-vitro* drug release profile of Pioglitazone Hydrochloride



### SUMMARY AND CONCLUSION:

Antidiabetic drugs, which undergoes extensive hepatic degradation, which have poor bioavailability for overcoming this problem fast disintegrating film (FDF) of antidiabetic drugs is formulated which avoids

extensive first pass metabolism and improvement in dissolution efficacy, disintegration time which results in improvement in bioavailability. The advantage of this formulation is such that in case of Shoot of blood glucose level in patient can take the drug without the usage of water.

In the present study efforts were taken for preparation of fast dissolving film of drug Pioglitazone HCl (Antidiabetic) formulation & consideration. Pioglitazone are a antidiabetic drug, which undergoes extensive hepatic degradation, which have bioavailability (83%) for overcoming this problem fast dissolving films of Pioglitazone Hydrochloride is formulated which avoids extensive first pass metabolism and improvement in dissolution efficacy, disintegration time which results in improvement in bioavailability.

Fast dissolving films of Pioglitazone Hydrochloride was prepared by solvent casting technique by using suitable combination of superdisintegrants and film forming polymer. The formulation F7 shows disintegration time less than 20 sec. and highest percentage drug release in 14 min of about 96.78%.

From the findings it can be concluded that:

1. This study shows that solubility and dissolution rate of Pioglitazone Hydrochloride can be enhance considerably by formulating in it as Oro dispersible film with Sodium starch glycolate as a super disintegrant in combination with Betacyclodextrine in a ration of 1:1 by solvent casting technique.
2. Formulation containing SSG and Betacyclodextrine (1:1) shows improves disintegration rate than that of pure drug.
3. An attempt to develop Fast dissolving film was achieved within view to improve bioavailability and enhancement of patient compliance.
4. Fast dissolving film of Pioglitazone Hydrochloride 15mg was prepared by using Solvent casting technique.
5. The IR study revealed that, polymers and excipients used were compatible with drug.
6. Formulated film shows compliance for various physiochemical properties such as drug content, film mass, surface pH, folding endurance, disintegration time, and content uniformity.
7. In-vitro release studies shows that formulation F7 shows 96% drug release within 14min. in comparison to other formulation.
8. Formulation F7 were selected for stability study on the basis of their better & satisfactory evaluation study parameter mainly with the disintegration time and percentage drug release.

#### **ACKNOWLEDGMENT:**

The author is thankful to Dr.V.V.P.F's College of Pharmacy, Ahmednagar for providing all the facilities for conducting the research work.

#### **REFERENCES**

1. C. S Sweetman, P S Blake. Martindale: the complete drug references, 36th edition, The pharmaceutical press publication; 2009. p. 1348-9.

2. United States of Pharmacopoeia 26 NF 21. NF monograph, The United States of Pharmacopoeial Convention; 2003. Official may 1, 2007.
3. Raymond CR, Paul JS, Quinn ME. Handbook of pharmaceutical excipients. 6th ed. London: Pharmaceutical press; 2009. p. 326-9.
4. Kibbe AH. Handbook of pharmaceutical excipients. 3rd ed. London: Pharmaceutical press; 2000.
5. Handbook of Pharmaceutical Excipients. The Pharmaceutical Society of Great Britain and American Pharmaceutical Association, 1986 : 113-214.
6. Cetylpalmitate, Cetyl alcohol, Isopropyl alcohol, Tween-80, Span-80, propyl paraben and methyl paraben in Hand Book of Pharmaceutical Excipients, Washington, American Pharmaceutical Association, 1st Edn. 1986; 63-68, 146-147, 184-186, 225-227, 244-245, 281-283.
7. American Pharmaceutical Association And The Pharmaceutical Society of Great Britain. Handbook of pharmaceutical excipients. Washington,London: American Pharmaceutical Association,The Pharmaceutical Society of Great Britain; 1986.
8. Masareddy RS, Kadia RV, Manvi FV. Development of mouth dissolving tablets of clozapine using two different techniques. Indian J Pharm Sci 2008;70(4):526-28.
9. Mahapatra AK, Murthy PN, Sahoo J, Biswal S, Sahoo SK. Formulation design and optimization of mouth dissolving tablets of levocetirizine hydrochloride using sublimation technique. Indian Journal of Pharmaceutical Education & Research 2008;43(1):39-45.
10. S. Kunte and P. Tandale. Fast dissolving strips: A novel approach for the delivery of verapamil. J Pharm Bioallied Sci. 2010 Oct-Dec; 2(4): 325–328
11. M. Nappinnai,\* R. Chandanbala, and R. Balajirajan Formulation and Evaluation of Nitrendipine Buccal Films Indian J Pharm Sci. 2008 Sep-Oct; 70(5): 631–635.
12. Bhardwaj V, Bansal V, Sharma PK. Formulation and Evaluation of Fast Dissolving Tablets of Amlodipine Besylate Using Different Super Disintegrants and Camphor as Sublimating Agent. Amer-Eurasian J Scient Res. 2010;5 (4):264-269.
13. Aqil M, Ali A, Sultana Y, Dubey K, Najmi AK and pillai KK. In vivo characterization of monolithic matrix type transdermal drug delivery systems of pinacidil monohydrte. AAPS Pharm Sci Tech 2006;7(1):E1-5.
14. Aqil M, Sultana Y, Ali A. Matrix type transdermal drug delivery systems of metoprolol tartrate: In vitro characterization. Acta Pharm 2003;53:119-25.
15. Aqil M, Ali A, Sultana Y, Najmi AK. Fabrication and evaluation of polymeric films for transdermal delivery of pinacidil. Pharmazie 2004;59(8):631-5.
16. Al-Saidan SM, Krishnaiah YSR, Chandrasekhar DV, Lalla JK, Rama B, Jayaram B, et al. Formulation of an hpmc gel drug reservoir system with ethanol-water as a solvent system and limonene as a

- penetration enhancer for enhancing in vitro transdermal delivery of nicorandil. *Skin Pharmacol Physiol* 2004;17:310-20.
17. Jain SK, Gupta SP. Effective and controlled transdermal delivery of metoprolol tartarate. *Indian J Pharm Sci* 2005;67(3):346-50.
  18. Shastri VP, Lee PJ, Ahmad N, Langer R, Mitragotri S. Evaluation of chemical enhancers in the transdermal delivery of lidocaine. *Int J Pharm* 2006;308:33-9.
  19. Barhate SD, Patel MM, Sharma AS, Nerkar P, Shankhpal G. Formulation and evaluation of transdermal drug delivery system of carvedilol. *J Pharm Res* 2009;2(4):663-5.
  20. Shin SC, Cho CW. Enhanced transdermal delivery of atenolol from the ethylenevinyl acetate matrix. *Int J Pharm* 2004;287:67-71.
  21. Singh BS and Kumar CP. Penetration enhancers for transdermal drug delivery of systemic agents. *J Pharm Res* 2007;6(2):44-50.
  22. Ren C, Fang L, li T, Wang M, Zhao L, He Z. Effect of permeation enhancers and organic acids on the skin permeation of indapamide. *Int J Pharm* 2008;350:43-7.
  23. Jain S, Joshi SC. Development of transdermal matrix system of captopril based on cellulose derivative. *Pharmacolgyonline* 2007;1:379-90.